tiprankstipranks
Trending News
More News >
Kewaunee Scientific Corp. (KEQU)
NASDAQ:KEQU

Kewaunee Scientific (KEQU) AI Stock Analysis

Compare
47 Followers

Top Page

KE

Kewaunee Scientific

(NASDAQ:KEQU)

61Neutral
Kewaunee Scientific displays strong financial performance with robust revenue growth and profitability, although it faces challenges in cash flow management. The stock is technically oversold, indicating potential short-term downward pressure. However, its low P/E ratio presents an attractive valuation for value investors. Overall, the company is fundamentally solid but requires improvements in cash flow to enhance its market position.

Kewaunee Scientific (KEQU) vs. S&P 500 (SPY)

Kewaunee Scientific Business Overview & Revenue Model

Company DescriptionKewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates through two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, its subidiaries, and a national distributor. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.
How the Company Makes MoneyKewaunee Scientific generates revenue through the sale of its laboratory and technical furniture products, which are custom-designed to meet the specific needs of its clients in various scientific and technical fields. The company's revenue model is primarily based on manufacturing and selling these products directly to customers or through a network of distributors. Key revenue streams include the sale of laboratory furniture systems, fume hoods, and other related products. Additionally, Kewaunee offers installation services, which provide an added layer of revenue. The company's earnings are significantly influenced by its ability to secure contracts from educational institutions, government laboratories, and private sector companies, as well as maintaining strong relationships with distributors and suppliers. Strategic partnerships and collaborations within the scientific community further bolster Kewaunee's market presence and contribute to its overall financial performance.

Kewaunee Scientific Financial Statement Overview

Summary
Kewaunee Scientific's financial performance is robust with strong revenue growth and profitability. The balance sheet reflects moderate leverage and efficient equity utilization. However, cash flow management poses challenges with negative free cash flow growth, highlighting the need for improved cash conversion. The company appears well-positioned but should focus on strengthening cash flows for sustained growth.
Income Statement
75
Positive
Kewaunee Scientific shows strong profitability with a TTM gross profit margin of 27.02% and a net profit margin of 7.99%. Revenue increased by 7.99% over the previous year, indicating positive growth. EBIT and EBITDA margins are healthy at 6.73% and 6.12% respectively, showcasing efficient operational performance. Overall, the company demonstrates robust revenue growth and profitability.
Balance Sheet
68
Positive
The debt-to-equity ratio stands at a manageable 0.36, reflecting moderate leverage. The return on equity is strong at 28.31%, highlighting efficient use of equity to generate profits. An equity ratio of 32.84% indicates a reasonable level of equity financing. The balance sheet suggests a stable financial position with a healthy equity base.
Cash Flow
60
Neutral
Free cash flow growth is negative at -74.37%, contrasting with a positive operating cash flow to net income ratio of 0.37, indicating cash flow challenges despite profitability. The free cash flow to net income ratio is 0.22, suggesting limited cash conversion. Overall, cash flow management requires improvement to better support operations and growth initiatives.
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
203.75M219.49M168.87M147.47M147.54M
Gross Profit
52.05M35.59M24.22M23.99M23.43M
EBIT
18.28M3.63M-2.61M-1.32M-2.35M
EBITDA
18.04M8.16M916.00K459.00K281.00K
Net Income Common Stockholders
18.75M1.36M-6.00M-3.61M-4.62M
Balance SheetCash, Cash Equivalents and Short-Term Investments
23.27M8.08M4.43M5.21M4.37M
Total Assets
134.77M118.90M118.77M89.38M83.93M
Total Debt
11.00M12.92M9.44M16.15M13.80M
Net Debt
-12.27M4.84M5.01M10.94M9.44M
Total Liabilities
78.56M80.41M82.59M47.90M45.23M
Stockholders Equity
54.76M37.41M35.69M41.24M38.41M
Cash FlowFree Cash Flow
15.19M-7.94M-9.79M-1.49M1.70M
Operating Cash Flow
19.56M-3.79M-7.88M912.00K4.16M
Investing Cash Flow
-4.37M-4.15M-1.91M-2.40M-2.46M
Financing Cash Flow
-3.01M14.93M11.03M1.98M-7.46M

Kewaunee Scientific Technical Analysis

Technical Analysis Sentiment
Negative
Last Price31.50
Price Trends
50DMA
41.98
Negative
100DMA
50.59
Negative
200DMA
46.24
Negative
Market Momentum
MACD
-2.92
Negative
RSI
33.41
Neutral
STOCH
25.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KEQU, the sentiment is Negative. The current price of 31.5 is below the 20-day moving average (MA) of 33.65, below the 50-day MA of 41.98, and below the 200-day MA of 46.24, indicating a bearish trend. The MACD of -2.92 indicates Negative momentum. The RSI at 33.41 is Neutral, neither overbought nor oversold. The STOCH value of 25.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KEQU.

Kewaunee Scientific Risk Analysis

Kewaunee Scientific disclosed 24 risk factors in its most recent earnings report. Kewaunee Scientific reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Kewaunee Scientific Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
ETETD
73
Outperform
$748.91M12.3412.86%5.37%-11.10%-23.77%
LZLZB
72
Outperform
$1.71B14.1612.40%2.10%1.81%8.09%
61
Neutral
$89.92M5.3333.52%9.44%102.67%
61
Neutral
$6.66B11.712.96%4.01%2.64%-20.91%
56
Neutral
$162.42M-3.83%4.43%-11.78%-13.89%
48
Neutral
$90.93M-5.89%9.92%-8.26%-233.72%
47
Neutral
$161.57M9.10%-12.36%37.69%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KEQU
Kewaunee Scientific
31.50
-3.68
-10.46%
BSET
Bassett Furniture
18.66
5.32
39.88%
ETD
Ethan Allen
29.45
1.92
6.97%
HOFT
Hooker Furniture
9.56
-6.97
-42.17%
LZB
La-Z-Boy Incorporated
41.31
8.76
26.91%
SNBR
Sleep Number
7.13
-6.93
-49.29%

Kewaunee Scientific Corporate Events

Private Placements and FinancingM&A TransactionsBusiness Operations and Strategy
Kewaunee Scientific Expands with Nu Aire Acquisition
Positive
Nov 1, 2024

Kewaunee Scientific Corporation has acquired Nu Aire, Inc. for $55 million, expanding its capabilities in the laboratory and technical product market. This acquisition allows Kewaunee to integrate Nu Aire’s well-regarded product line, which includes biological safety cabinets and CO2 incubators, into its offerings. The deal, financed partially through a loan from PNC Bank, enhances Kewaunee’s market presence and provides new growth opportunities, especially in regions previously untapped by Kewaunee. This strategic move positions the company for continued growth in recession-resistant industries like healthcare and life sciences.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.